| Literature DB >> 19606092 |
D Aeschbach1, B J Lockyer, D-J Dijk, S W Lockley, E S Nuwayser, L D Nichols, C A Czeisler.
Abstract
Oral melatonin (MEL) can improve daytime sleep, but the hormone's short elimination half-life limits its use as a hypnotic in shift workers and individuals with jet lag or other sleep problems. Here we show, in healthy subjects, that transdermal delivery of MEL during the daytime can elevate plasma MEL and reduce waking after sleep onset, by promoting sleep in the latter part of an 8-h sleep opportunity. Transdermal MEL may have advantages over fast-release oral MEL in improving sleep maintenance during adverse circadian phases.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19606092 PMCID: PMC2909186 DOI: 10.1038/clpt.2009.109
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN: 0009-9236 Impact factor: 6.875